These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30675707)

  • 21. Diagnostic and Therapeutic Implications of Erectile Dysfunction in Patients with Cardiovascular Disease.
    Gandaglia G; Briganti A; Montorsi P; Mottrie A; Salonia A; Montorsi F
    Eur Urol; 2016 Aug; 70(2):219-22. PubMed ID: 26873841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of erectile dysfunction and peculiarities of its treatment in men with high cardiovascular risk].
    Mamedov MN; Digigova RT; Sharvadze GG; Ugurchieva ZO; Kovrigina MN; Stroeva MV
    Kardiologiia; 2010; 50(11):85-90. PubMed ID: 21526570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
    Basal S; Wambi C; Acikel C; Gupta M; Badani K
    BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding Erectile Dysfunction in Hypertensive Patients: The Need for Good Patient Management.
    Hernández-Cerda J; Bertomeu-González V; Zuazola P; Cordero A
    Vasc Health Risk Manag; 2020; 16():231-239. PubMed ID: 32606719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
    Kostis JB; Jackson G; Rosen R; Barrett-Connor E; Billups K; Burnett AL; Carson C; Cheitlin M; Debusk R; Fonseca V; Ganz P; Goldstein I; Guay A; Hatzichristou D; Hollander JE; Hutter A; Katz S; Kloner RA; Mittleman M; Montorsi F; Montorsi P; Nehra A; Sadovsky R; Shabsigh R
    Am J Cardiol; 2005 Jul; 96(2):313-21. PubMed ID: 16018863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erectile dysfunction, phosphodiesterase-5 inhibitor use and risk of cardiovascular disease and mortality in people with diabetes: A systematic review and meta-analysis.
    Seidu S; Cebrián A; Kunutsor SK; Khunti K
    Prim Care Diabetes; 2022 Oct; 16(5):601-613. PubMed ID: 36114105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PDE5 inhibitors: targeting erectile dysfunction in diabetics.
    Francis SH; Corbin JD
    Curr Opin Pharmacol; 2011 Dec; 11(6):683-8. PubMed ID: 21924956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase-5 inhibitors could be efficacious in the treatment of erectile dysfunction after radiotherapy for prostate cancer: a systematic review and meta-analysis.
    Yang L; Qian S; Liu L; Pu C; Yuan H; Han P; Wei Q
    Urol Int; 2013; 90(3):339-47. PubMed ID: 23221333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors.
    Sung HH; Ahn JS; Kim JJ; Choo SH; Han DH; Lee SW
    Andrology; 2014 Jan; 2(1):45-50. PubMed ID: 24194017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
    Gopal A; Sharma T; Calkins JB
    J Cardiovasc Pharmacol; 2021 Sep; 78(3):372-376. PubMed ID: 34074904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-Morbid Erectile Dysfunction (ED) and Antidepressant Treatment in a Patient - A Management Challenge?
    Zainol M; Sidi H; Kumar J; Das S; Ismail SB; Hatta MH; Baharuddin N; Ravindran A
    Curr Drug Targets; 2019; 20(2):182-191. PubMed ID: 28302034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newer phosphodiesterase inhibitors: comparison with established agents.
    McNamara ER; Donatucci CF
    Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals.
    Moazin MS; Baazeem A; Al-Bakri A; Dayel AA; Amir A; Sifri SA; Reda M; Bashraheel F; Alfakhri A; Hamdy Y; Elshaer F
    J Comp Eff Res; 2024 Jul; 13(7):e230155. PubMed ID: 38775343
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
    Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
    J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of the risk factors of erectile dysfunction and phospho diestrase type 5 inhibitors usage among Egyptian population with erectile dysfunction: A cross-sectional survey.
    Elnaser Mohamed TA; Kamel II; Abdelaal AMA; Mohammad AF; GamalEl Din SF
    Rev Int Androl; 2021; 19(4):249-258. PubMed ID: 33773939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erectile dysfunction in heart failure patients: a critical reappraisal.
    Alberti L; Torlasco C; Lauretta L; Loffi M; Maranta F; Salonia A; Margonato A; Montorsi F; Fragasso G
    Andrology; 2013 Mar; 1(2):177-91. PubMed ID: 23339018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex?
    McCabe MP; Althof SE
    J Sex Med; 2014 Feb; 11(2):347-63. PubMed ID: 24251371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction.
    Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S
    Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.